Artelo Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

LEASE (Tables)

LEASE (Tables)

9 Months Ended

Sep. 30, 2024

Schedule of operating lease right-of use assets and lease information

		Nine months ended
		September 30
		2024				2023

Lease cost
Operating lease cost		$	24			$	30

Other information
Cash paid for operating cash flows from operating leases		$	22			$	32
Right-of-use assets obtained in exchange for new operating lease liability		$	111			$	-

Weighted-average remaining lease term — operating leases (year)			2.83				0.92
Weighted-average discount rate — operating leases			7.50	%			3.00	%

Schedule of operating lease liabilities future minimum lease payments

		Total
Year Ended December 31,
2024 (for the 3 months remaining)		$	10
2025			42
2026			43
2027			30
Thereafter			-
			125
Less: Imputed interest			(13	)
Operating lease liabilities			112

Operating lease liability - current			34
Operating lease liability - non-current		$	78